跳至主要内容
临床试验/NCT05540678
NCT05540678终止不适用

The FibreGum Study - Changing the Course of Obesity in Children

Insel Gruppe AG, University Hospital Bern2 个研究点 分布在 1 个国家目标入组 93 人开始时间: 2022年11月30日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
入组人数
93
试验地点
2
主要终点
Reduction in the Body Mass Index (BMI) Z-score

研究概览

简要总结

The aim of this study is thus to assess the effect of a chewing gum containing fibres on body weight, metabolism and the oral and intestinal microbiomes in a population of obese children.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
10 Years 至 16 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Informed Consent according to International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (ICH/GCP) regulations prior to any study specific procedures
  • Obesity as determined by a BMI ≥97th percentile using the Swiss paediatric, age- and sex-matched growth charts
  • Newly referred within the last month to a tertiary weight management clinic
  • Participant willing to use the study specific monitoring app on his/her own or legal representatives' smartphone

排除标准

  • Antibiotic administration in the last 6 months
  • Pre- or probiotic treatment in the last 6 weeks
  • Any professionally supervised treatment for weight management within the last year
  • Consumption of more than one nicotine product per month (e.g. cigarette, gum)
  • Adolescent females: any stages of known pregnancy or lactation period
  • Congenital disorder affecting the cardiovascular, hepatic or respiratory system in a relevant way (as per PI's or specialist's evaluation)
  • Malignant disease on treatment or previous tumour affecting the appetite system (e.g., suprasellar, hypothalamic tumours)
  • Systemic antibiotic or anti-inflammatory medication (e.g. systemic intake of glucocorticoids) over the last 7 days
  • Known eating disorder (medically diagnosed)
  • Participation in another investigation with an investigational drug within the 30 days preceding and during the present investigation
  • Dependency from the sponsor or the clinical investigator
  • Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, etc. of the participant and/or legal representative

研究组 & 干预措施

Placebo

Placebo Comparator

Chewing gum containing maltitol powder

干预措施: Placebo (Dietary Supplement)

Investigational

Experimental

chewing gums containing fibers

干预措施: FibreGum (Dietary Supplement)

No-treatment control

No Intervention

No study chewing gum

结局指标

主要结局

Reduction in the Body Mass Index (BMI) Z-score

时间窗: 6 months

Difference in the BMI Z-scores measured at study start and study completion

次要结局

  • Fasting blood glucose change(6 months)
  • Fasting insulin change(6 months)
  • Systolic and diastolic blood pressures changes(6 months)
  • HOmeostatic Model Assessment of Insulin Resistance (HOMA-IR) index change(6 months)
  • Hemoglobin A1c (HbA1c) change(6 months)
  • Intestinal health(6 months)
  • Alanine Aminotransferase (ALAT) change(6 months)
  • Thyroid-Stimulating Hormone (TSH) change(6 months)
  • Ferritin change(6 months)
  • Proteinuria(6 months)
  • Lipid-profiles change(6 months)
  • Differential blood count change(6 months)
  • Calprotectin and lipocalin-2 change in stool(6 months)
  • Oral health(6 months)
  • Descriptive analysis of treatment adherence using data from an adherence-tracking app(6 months)
  • Calcifediol (25OH-Vitamin D3) change(6 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验